SIU 2018: Management of Grade Group 2 Prostate Cancer, Radical Therapy

Seoul, South-Korea (UroToday.com) In this session, a case of intermediate risk prostate cancer was presented and various treatment options were discussed. In this specific session management with radical therapy was recommended. The hypothetical patient was a 65-year-old healthy man, who is a non-smoker, with mild hypertension, and a mild decrease of erectile function with an International Prostate Symptom Score (IPSS) of 12.

SIU 2018: Management of Grade Group 2 Prostate Cancer, Focal Therapy

Seoul, South-Korea (UroToday.com) In this session, a case of intermediate risk prostate cancer was presented and various treatment options were discussed. In this presentation management with focal therapy was recommended. The hypothetical patient was a 65-year-old healthy man, who is a non-smoker, with mild hypertension, and a mild decrease of erectile function with an International Prostate Symptom Score (IPSS) of 12.

SIU 2018: Management of Grade Group 2 Prostate Cancer, Surveillance

Seoul, South-Korea (UroToday.com) A case of intermediate risk prostate cancer was presented and various treatment options were discussed in this session. In this presentation management with active surveillance was recommended. The hypothetical patient was a 65-year-old healthy man, who is a non-smoker, with mild hypertension, and a mild decrease of erectile function with an International Prostate Symptom Score (IPSS) of 12.

SIU 2018: PSA Cutpoint Should be 1.5

Seoul, South-Korea (UroToday.com) E. David Crawford, MD gave a presentation focusing on why PSA cut-off should be changed from 4 ng/ml to 1.5 ng/ml.  According to Dr. Crawford, when interacting with practicing urologists and family physicians, most are not happy with the current state of prostate cancer screening and diagnosis. The most common areas of concern include screening parameters, informed decisions, and risks and benefits of prostate cancer screening. However, all agree that there is significant value to prostate cancer screening.

SIU 2018: FSH and Prostate Cancer

Seoul, South-Korea (UroToday.com) Jehonathan H. Pinthus, MD presented the importance of Follicle Stimulating Hormone (FSH) in prostate cancer. The hypothalamus in the brain secretes Gonadotropin-releasing hormone (GnrRH) that causes FSH to be secreted from the pituitary gland, which in turn, causes Sertoli cells in the testicle to secrete Inhibin, harboring a negative feedback on FSH secretion. GnRH also causes an increase in the secretion of Luteinizing hormone (LH) from the pituitary gland, which in turn, causes an increase in the secretion of testosterone by the Leydig cells in the testicle. Testosterone causes negative feedback inhibition on GnRH secretion from the hypothalamus.

SIU 2018: Prostate Cancer Screening: European Perspective

Seoul, South-Korea (UroToday)  Dr. Recker began his presentation on the status of prostate cancer screening in Europe with stating that PSA is a gatekeeper. Starting PSA measurements in young men will give us information regarding their long-term risk and mortality from prostate cancer. Additionally, it has been shown that organized screening is superior to opportunistic screening with a cumulative increased incidence of prostate cancer of 9.9%, with overdiagnosis two times higher and no reduced mortality. In other words, a single PSA test cannot detect prostate cancer efficiently enough. 

SIU 2018: Prostate Cancer Screening: Latin American Perspective

Seoul, South-Korea (UroToday) There is significant variation of prostate cancer rates around the world. Prostate cancer incidence rates increased in nearly all countries, except in a few high-income countries. In contrast, the increase in prostate cancer mortality mainly occurred in lower resource settings, with declines largely confined to high-resource countries.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe